PMCB - PharmaCyte Biotech Inc.
Company Overview
Website: http://www.pharmacytebiotech.com/
Effective January 6, 2015, Nuvilex, Inc. ("Company") changed its legal corporate name to "PharmaCyte Biotech, Inc." The name change was effected through a short-form merger pursuant to Section 92A.180 of the Nevada Revised Statutes. A wholly-owned subsidiary of the Company was merged with and into the Company, with the Company as the surviving entity of the merger.
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.
Pipeline
Pancreatic Cancer
PharmaCyte Biotech holds the exclusive, worldwide rights to use the Cell-in-a-Box® cellulose-based live cell encapsulation technology for the development of a treatment for pancreatic cancer. PharmaCyte Biotech is using its pancreatic cancer treatment (the combination of the Cell-in-a-Box® technology with low doses of the anticancer prodrug ifosfamide) in an attempt to combat pancreatic cancer on two fronts. On the basis of previous Phase 1/2 and Phase 2 clinical trials, this treatment has been shown to be safe and effective in patients with advanced, inoperable pancreatic cancer.
Effectiveness of PharmaCyte Biotech's Treatment in Alleviating Symptoms Associated with Pancreatic Cancer and other Abdominal Cancers
PharmaCyte Biotech is tackling the two major disease-associated symptoms that are suffered by patients with pancreatic cancer, namely the intractable and virtually untreatable pain and the accumulation of fluid (known as malignant ascites) in the abdomen that is extremely uncomfortable for patients with pancreatic cancer. Because this ascites fluid can contain cancer cells and these cells can seed and form new tumors, oncologists must remove ascites fluid on a regular and frequent basis. This is costly and painful.
The first preclinical study on the accumulation of ascites fluid has just been completed in the United States by Translational Drug Development (TD2), one of the premier Contract Research Organizations (CRO) in the U.S. that specializes in the development of cancer drugs and treatments. In this study, a mouse model system was used in which immunosuppressed mice were implanted with human ovarian tumor cells. These cells were chosen because they grow rapidly and produce significant amounts of ascites fluid.
Read Full Article Here http://www.pharmacytebiotech.com/
Financials & Filings
Visit: http://www.otcmarkets.com/stock/PMCB/company-info to see complete details.
News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
GlobeNewswire (Tue, Feb 24)
PharmaCyte Biotech's Scientific Advisory Board Chairman Publishes Review Article on the Pathology of Pancreatic Cancer
http://finance.yahoo.com/news/pharmacyte-biotechs-scientific-advisory-board-143000677.html
GlobeNewswire (Thu, Feb 19)
PharmaCyte Biotech Initiates Expanded Follow-up Study in the United States on the Accumulation of Malignant Ascites Fluid
http://finance.yahoo.com/news/pharmacyte-biotech-initiates-expanded-study-143000583.html
GlobeNewswire (Fri, Feb 13)
PharmaCyte Biotech Diabetes Consortium Member Publishes Review Article on Use of Genetic Engineering to Treat Diabetes
http://finance.yahoo.com/news/pharmacyte-biotech-diabetes-consortium-member-140000061.html
GlobeNewswire (Tue, Feb 10)
PharmaCyte Biotech's International Diabetes Consortium Sets Path Forward to Develop Novel Treatment for Diabetes
http://finance.yahoo.com/news/pharmacyte-biotechs-international-diabetes-consortium-140000018.html
Marketwired (Fri, Feb 6)
PharmaCyte Biotech's Diabetes Treatment: How Would It Work?
http://finance.yahoo.com/news/pharmacyte-biotechs-diabetes-treatment-140000756.html
Marketwired (Wed, Feb 4)
PharmaCyte Biotech Officially Begins Development of Diabetes Treatment With First Preclinical Study
http://finance.yahoo.com/news/pharmacyte-biotech-officially-begins-development-140000175.html
Contact
12510 Prosperity Drive
Suite 310
Silver Spring, MD 20904
Website: http://www.PharmaCyteBiotech.com
Phone: (917) 595-2850
Email: info@PharmaCyteBiotech.com
Goodies Newsletter Sign Up http://www.stockgoodies.com
WANT A QUICKER WAY TO GET OUR ALERTS?
TEXT "Stock" to 31279
Follow Us on Twitter
http://twitter.com/StockGoodies
Follow Us on Facebook
http://www.facebook.com/groups/STOCKGOODIES
Follow Us on PennyStockTweets
http://www.pennystocktweets.com/profile/StockGoodies
Contact Us admin@stockgoodies.com
